Henry Schein (NASDAQ:HSIC) is poised to release its second-quarter 2025 earnings data, a highly anticipated event for investors monitoring the healthcare products and services giant. Analysts are keenly awaiting these financial disclosures, which are expected to shed light on the company’s performance and future trajectory in a dynamic market. This report will provide crucial insights into whether the company has met, exceeded, or fallen short of market expectations, influencing its stock trajectory.
For the upcoming Q2 2025 period, market analysts have set specific benchmarks for Henry Schein’s financial performance. Consensus estimates project the company to report earnings of $1.19 per share. Alongside the earnings per share, revenue forecasts indicate a target of $3.22 billion for the quarter, highlighting the significant scale of its operations. These figures are critical for gauging the company’s operational efficiency and market penetration.
Looking back at the first quarter of 2025, Henry Schein demonstrated a notable financial performance, having announced its results on Monday, May 5th. The company successfully reported earnings of $1.15 per share, surpassing analysts’ consensus estimates of $1.11 by a margin of $0.04. This positive earnings surprise indicated a stronger-than-expected operational quarter, providing a boost to investor confidence.
Despite the earnings beat, the firm’s revenue for the first quarter stood at $3.17 billion, slightly below analysts’ expectations of $3.24 billion. Further financial metrics revealed a net margin of 3.21% and a robust return on equity of 14.87%. Compared to the same quarter last year, the company’s revenue saw a marginal decrease of 0.1%, while earnings per share improved from $1.10. These figures offer a comprehensive view of Henry Schein’s profitability and efficiency.
The company’s stock, HSIC, opened at $67.98 on Friday, reflecting recent market activity and investor sentiment. Henry Schein maintains a substantial market capitalization of $8.27 billion, underscoring its significant presence in the industry. Its valuation metrics, including a P/E ratio of 21.24, a P/E/G ratio of 2.20, and a beta of 0.82, provide a detailed snapshot of its current market standing and risk profile.
Furthermore, an analysis of Henry Schein’s balance sheet reveals a debt-to-equity ratio of 0.50, a current ratio of 1.38, and a quick ratio of 0.75, indicating healthy financial management. The stock’s recent trading performance shows a fifty-day moving average price of $71.62 and a two-hundred-day moving average price of $71.33. These moving averages are often used by investors to identify trends and potential price movements.
Shares of HSIC have fluctuated within a defined range over the past year, with a one-year low of $60.56 and a one-year high of $82.49. This historical price movement provides context for the current stock analysis and helps investors understand its volatility. The upcoming earnings report could significantly impact where the stock trades within or beyond this established range.
Henry Schein has recently been the subject of numerous analyst reports, reflecting keen interest from the financial community in its future prospects. Wells Fargo & Company, Robert W. Baird, and Barrington Research are among the firms that have adjusted their price targets and ratings, with some cutting targets while others maintained or upgraded ratings. This varied analyst sentiment contributes to the broader investor outlook for the company.
Based on data from MarketBeat.com, the consensus among thirteen research analysts currently rates Henry Schein with an average “Hold,” including nine hold ratings and four buy ratings. The collective analyst target price stands at $78.08. These projections and ratings are crucial for investors formulating their strategies around Henry Schein’s stock performance following the anticipated Q2 2025 earnings release.
